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Abstract
Background:  Antisense (AS) induced down-regulation of uPAR in ACCS adenoid-cyctic
carcinoma cells decreased the cellular adhesion and invasion on various extracellular matrices.
Additionally, ACCS-AS cells showed an increased EGFR expression and other behavioral
similarities to NA-SCC, a typical highly proliferative but less invasive squamous cell carcinoma
(SCC) cell line of the head and neck. ACCS, ACCS-AS and NA-SCC cells were used to elucidate
the relationships between uPAR down-regulation and EGFR inhibition.
Results:  Tyrosine kinase inhibitor Gefitinib (IRESSA, ZD 1839) significantly reduced the
chemotactic cell migration and adhesion. This was associated with reduced EGFR and ERK
activation. In addition, anti-proliferative effect of gefitinib in uPAR down-regulated ACCS-AS was
significantly higher than parental ACCS, to levels comparable to gefitinib-sensitive NA-SCC cells.
This was evidenced by both reduced dosage and duration of treatment. Furthermore, time-lapse
videography showed that treatment with gefitinib was also associated with cell rounding and loss
of pseudopodia, mostly in ACCS-AS rather than parental ACCS cells. There were also evidences
of formation and exocytosis of vacuole-like structures in ACCS-AS, as well as NA-SCC, but not in
parental ACCS cells. Interestingly, immunocytochemistry showed that the exocytotic vacuoles
actually contained de-activated EGFR.
Conclusion: Our results suggested that down-regulation of uPAR affected the fate of EGFR in high
EGFR expressing cells. Furthermore, combining the uPAR down-regulation with EGFR inhibition
showed a synergistic anti-tumor effect and might provide an alternative method to increase anti-
proliferative effect of tyrosine kinase inhibitors with lower doses and duration to reduce their side
effects during cancer control.
Background
Urokinase Plasminogen Activator Receptor (uPAR) is a
three-domain glycoprotein linked to the cell membrane
by a glycosylphosphatidylinositol. It facilitates cellular
movement, providing a proper condition for tumor-cell
invasion, chemotaxis, and cellular adhesion [1,2]. Down-
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regulation of uPAR by using antisense (AS) or gene-ther-
apy approaches has increased survival in animal models
of cancer [3,4]. The stable transfection of uPAR antisense
to glioblastoma clones resulted in an inability of the cells
to generate tumors when transplanted into nude mice [5]
and reduced invasiveness in-vitro [5]. Adenovirus-medi-
ated down-regulation of bicistronic constructs of uPA and
uPAR expression inhibited cell migration, invasion and
tumor-induced capillary formation[4]. In another study,
stably transfected glioma cells expressing the amino ter-
minal fragment (ATF) domain (residues 1–46) of uPA,
which binds uPAR, did not form tumors in nude mice[6].
However, studies have demonstrated that both uPA-/- and
uPAR-/-  homozygous deficient mice develop normally
without any apparent growth defect [7,8]. Therefore, tar-
geting and inhibiting the uPA/uPAR system for cancer
therapy is not likely to cause deleterious effects on normal
cells and would be an appropriate approach for adjuvant
therapy.
Epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein with specific tyrosine kinase activity,
serving to regulate proliferation and differentiation of epi-
dermal cells[9,10]. In human solid tumors, over-activa-
tion and/or dysregulation of EGFR promotes processes
involved in tumor progression, including invasion, angio-
genesis, metastasis, and resistance to anticancer treatment
with blocking apoptosis [11-13]. Activation of this recep-
tor actually leads to recruitment and phosphorylation by
protein kinases (PKs) of several intracellularsubstrates,
which, in turn, engage mitogenic signaling and other
tumor-promoting activities. Therefore, over 20 years ago,
EGFR signaling inhibition was proposed as a target for
cancer therapy[14].
Both EGFR and uPAR receptors interact with each other at
many levels[15]. Part of cellular signaling from uPAR
appears to occur through EGFR transactivation [16,17].
Furthermore, abrogation of EGFR signaling in tumor
model systems blocks uPAR-associated invasiveness
through an extracellular matrix [18] and growth of tumors
in animal models [16,19]. Thus, EGFR appears to be a
necessary element for uPAR-mediated tumor progression.
On the other hand, some workers have shown that uPAR
is also necessary for EGF to induce proliferation of mouse
embryonic cells and some cancer cells [20].
The development of EGFR kinase inhibitors was greeted
with tremendous enthusiasm in the therapy of squamous
cell carcinoma of the head and neck (SCCHN) based on
the nearly universal expression of this receptor in this can-
cer, the negative prognostic associations with expression,
and robust preclinical data[21]. Furthermore, clinical tri-
als to date have demonstrated modest activity of these
drugs as single agents with reproducible major response
rates of 5% to 15% in SCCHN depending on agent, dose,
and schedule. However, the biology of responsiveness to
these agents remains unclear[21,22]. Therefore, the mech-
anisms involved in resistance against these inhibitors as
well as their side-effects are still important problems in
using these anti-cancer agents.
Gefitinib ("Iressa" or ZD1839, from AstraZeneca. Co.) is
an orally active, selective EGFR tyrosine kinase inhibitor
blocking signal transduction pathways implicated in the
proliferation and survival of cancer cells[23]. Our study
focused on relationship between status of uPAR and EGFR
pathway in head and neck cancer cells treated by tyrosine-
kinase inhibitor gefitinib. Our results showed how down-
regulation of uPAR was associated with changed EGFR
trafficking upon gefitinib treatment. They also suggested
that combined uPAR antisense treatment with inhibition
of EGFR activation might improve the efficiency of the
EGFR-targeting anti-cancer therapy and could be consid-
ered as a new therapeutic strategy.
Results
uPAR antisense down-regulation and its effect on EGFR
uPAR antisense (AS) transfection of ACCS cells effectively
down-regulated the mRNA expression of uPAR at least in
five isolated ACCS-AS clones. uPAR expression in a repre-
sentative clone is shown (Fig. 1,A). The uPAR levels in
ACCS-AS cells reduced to the levels comparable to NA-
SCC cell, a typical highly proliferative/less invasive squa-
mous cell carcinoma (SCC) cell line of the head and neck,
normally expressing low levels of uPAR (Fig. 1, A)(See
also Additional file 1 for comparing the protein level).
ACCS generally showed low expression of EGFR (Fig. 1,
B). However, antisense-induced uPAR down-regulation
resulted in up-regulated expression of EGFR in ACCS-AS
cells (Fig. 1, B). NA-SCC also showed constitutively high
expression of EGFR mRNA (Fig. 1, B).
Effect of Tyrosine kinase inhibition on cell proliferation
To demonstrate whether inhibition or stimulation of
increased EGFR in uPAR down-regulated cells has any
effect on their growth, we evaluated the cellular prolifera-
tion in uPAR down-regulated ACCS-AS cells and com-
pared the results with parental ACCS and NA-SCC cells.
We used MTT assay to evaluate the cellular proliferation
and measured the combined effect of uPAR down-regula-
tion and gefitinib treatment on growth potential of the
cells in vitro. The proliferation rate was compared to EGF-
stimulated or non-stimulated cellular proliferation (Fig.
2). MTT assay showed that although gefitinib inhibited
cell proliferation and resulted in cell death in all exam-
ined cells, the intensity of response was not same among
the cells. In fact, gefitinib inhibited cellular proliferation
almost equally in high EGFR/low uPAR expressing NA-Molecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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SCC and ACCS-AS cells at 0.5 μM (Fig. 2, A). However, in
parental ACCS cells, reversely expressing high uPAR/low
EGFR profile, the effect was significantly lower (p < 0.05)
and 7–10 times higher doses were required to achieve
similar effects. Comparing the effects of EGFR stimulation
by EGF and its inhibition by gefitinib showed that
although EGFR inhibition had anti- proliferative effect,
the EGF-induced stimulation of EGFR did not signifi-
cantly alter total cellular proliferation in the examined
cells (Fig 2, B).
Tyrosine kinase inhibition reduced cell adhesion and 
chemotactic migration
We have previously demonstrated that uPAR antisense
treatment reduced the cell adhesion on various extracellu-
lar matrices (ECMs) [24]. In this study, we investigated the
effect of gefitinib on the cell adhesion and chemotactic
migration upon same ECM,i.e., collagen I (Fig. 3). Cellu-
lar adhesion in non-treated ACCS-AS cells was compara-
tively lower than the parental ACCS. NA-SCC cells
showed the lowest adhesion. Gefitinib showed an inhibi-
tory effect on the cellular adhesion in all cells (Fig. 3, A).
However, comparing to non-treated cells, inhibitory effect
of gefitinib on adhesion was not different between paren-
tal ACCS and ACCS-AS cells.
Cellular chemotactic migration was also evaluated using
modified Boyden chamber as it is described in methods.
Chemotactic migration in non-treated ACCS-AS cells was
also comparatively lower than parental ACCS. NA-SCC
cells showed the lowest migration. Gefitinib also affected
cell chemotactic migration. In fact, gefitinib inhibited cell
chemotactic migration over collagen I in all of examined
cells. However, the reduced chemotactic migration was
more significant in ACCS-AS cell line, compared with
ACCS (p < 0.05)(Fig. 3, B).
Tyrosine kinase inhibition affected the activation of EGFR 
and its downstream molecules
Increased expression of EGFR in uPAR anti-sense trans-
fected cells indicated a significant change in metabolism
of EGFR. Therefore, next we studied the activation status
of EGFR in the parental ACCS and uPAR down-regulated
ACCS-AS cells showing increased EGFR expression. Acti-
vation status of EGFR in NA-SCC cells was also investi-
gated for comparison (Fig 4). Gefitinib de-activated the
auto-activated EGFR in the cells (Fig. 4). This de-activa-
tion was especially noted in ACCS-AS, as early as 30 min-
utes. However, in ACCS, the de-activation of EGFR was
comparatively lower and later (60 minutes). In the NA-
SCC cells also gefitinib effectively de-activated the EGFR
as early as 30 minutes.
Anti-sense induced down-regulation of uPAR was accompanied by an increased mRNA expression of EGFR n Figure 1
Anti-sense induced down-regulation of uPAR was accompanied by an increased mRNA expression of EGFR n: 
(A) RT- PCR confirmed the uPAR down-regulation in ACCS-AS cells and constitutively low uPAR expression in NA-SCC 
cells. (B) ACCS-AS cells showed marked increase in mRNA expression of EGFR, compared to the parental ACCS cells. Con-
stitutive high expression of EGFR in NA-SCC cells is also shown.
uPAR mRNA
0.00E+00
5.00E-02
1.00E-01
1.50E-01
2.00E-01
2.50E-01
A
C
C
S
A
C
C
S
-
A
S
N
A
-
S
C
C
EGFR mRNA
0.00E+00
5.00E+00
1.00E+01
1.50E+01
2.00E+01
A
C
C
S
A
C
C
S
-
A
S
N
A
-
S
C
C
AB
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
ᄼMolecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
Page 4 of 13
(page number not for citation purposes)
The effect of Tyrosine kinase inhibition on cellular proliferation determined by MTT assay Figure 2
The effect of Tyrosine kinase inhibition on cellular proliferation determined by MTT assay: (A) the effects of 
increasing concentrations of gefitinib on growth of ACCS, ACCS-AS and NA-SCC cells are shown. Cells were incubated with 
vehicle, i.e., non-stimulated, or increasing concentration of gefitinib for 24, 48, and 72 hours. (B) Comparison of cellular 
growth in response to gefitinib (3.75 μM), EGF (100 ng/ml) and vehicle i.e., non-stimulated. The bars represent SD of results of 
separate wells. * p < 0.05, versus similar dosage in parental ACCS cells at 24 and 48 hrs. ** p < 0.05, versus similar dosage in 
ACCS cells at 24 and 48 hrs.
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The effect of Tyrosine kinase inhibition on cell adhesion and chemotactic migration Figure 3
The effect of Tyrosine kinase inhibition on cell adhesion and chemotactic migration: The effect of gefitinib on cell 
adhesion (A) and chemotactic migration (B) was evaluated on collagen I as ECM. Gefitinib reduced both cell adhesion and 
chemotactic cell migration in the three cell lines. The inhibitory effect of gefitinib on chemotactic cell migration was more sig-
nificant in ACCS-AS cells, compared to parental ACCS cells, suggesting a synergism between the dual inhibition of uPAR and 
EGFR signaling on cellular migration. The low adhesion and chemotactic migration of NA-SCC cells are also shown. The bars 
represent SD of results of separate wells. *p < 0.05, non-treated versus gefitinib-treated cells.
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ERK is a main EGFR downstream signal mediator com-
monly evaluated after EGFR-targeted therapy. To investi-
gate whether gefitinib affect the downstream mediators of
EGFR in ACCS-AS cells with increased EGFR expression,
the activation status of ERK pathway was also studied. The
results showed that tyrosine kinase inhibition by gefitinib
was associated with de-activation of ERK. Gefitinib actu-
ally affected ERK activation almost in similar pattern as
EGFR (Fig. 4). Furthermore, comparing to ACCS, the de-
activation in ACCS-AS cells was comparatively more sig-
nificant.
Cyclin D1 expression is also linked to the stimulation or
inhibition of growth factors-related signals including
EGFR[25]. The Cyclin D1 expression was studied by
immunoblotting. Cyclin D1 expression was also reduced
in the three cell lines upon gefitinib treatment indicating
effective inhibition of EGFR (Fig. 4).
Morphological changes upon inhibition of EGFR activation
Our previous study showed that uPAR down-regulation
was associated with some morphologic changes in the
cells plated on various ECMs, especially regarding their
cytoplasmic projections [24]. In this study, the effects of
Tyrosine kinase inhibition on cellular morphology were
evaluated (Fig. 5). Gefitinib had a striking effect on cellu-
lar morphology. In fact, gefitinib treatment resulted in cell
rounding and loss of pseudopodia which was more
marked in ACCS-AS cells, compared with parental ACCS
cells (Fig. 5, A). Using time-lapse videography, we actually
observed the detailed events of cellular rounding of the
cells upon gefitinib treatment [Additional file 2, 3 and 4].
The representative photomicrographs taken at 0, 5, 20,
and 90 minutes are shown (Fig. 5, A). This was observed
earlier in single cells. Then cells in cluster rounded conse-
quently and exited from cell- cell junctions (Fig. 5, A, red
arrowheads).
Cellular rounding was followed by formation of vacuole-
like structures especially in ACCS-AS cells (Fig. 5, B). The
appearance of dark vacuoles in ACCS-AS cells was docu-
mented with time-laps videography showing the detailed
process of vacuole formation [Additional file 2, 3 and 4].
The formed vacuoles seemed to leave the cells as exocyto-
sis sacs in these cells [Fig. 5, B and Additional file 2, 3].
NA-SCC cells with high EGFR/low uPAR profile also
showed similar morphological findings to ACCS-AS cells
[Additional file 4]. In contrast, the time-laps videography
The effect of Tyrosine-Kinase inhibition on activation of EGFR and its down-stream signaling molecules Figure 4
The effect of Tyrosine-Kinase inhibition on activation of EGFR and its down-stream signaling molecules: Gefit-
inib inhibited the phosphorylation of EGFR and ERK and reduced Cyclin D1 expression in all cells. Total EGFR and total ERK 
are also shown for comparison. β-actin western blots and Coomassie blue staining of gels were used for confirmation of equal 
loading.
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Formation and exocytosis of vacuole-like structures upon inhibition of EGFR activation in uPAR down-regulated cells Figure 5
Formation and exocytosis of vacuole-like structures upon inhibition of EGFR activation in uPAR down-regu-
lated cells: (A) Gefitinib led to reduced spreading and cell rounding which was more obvious in ACCS-AS cells. (B) There 
was also vacuolar formation observed as early as 10 minutes in ACCS-AS cell lines which continued and affected most of cell 
population with time. Representative vacuole formations on ACCS-AS cells (red arrowheads) are shown. Time-lapse videogra-
phy also showed that formed vacuoles were exocytosed (see supplemented data). An example of masses speculated to be 
already exocytosed vacuole sacs are shown (green arrowheads).Molecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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did not show any obvious evidence indicating formation
of such vacuoles in ACCS cells.
The vacuole-like structure contained de-activated EGFR
Next we studied the nature and contents of vacuole-like
structures. Immunocytochemistry with anti-EGFR showed
that these vacuoles actually contained EGFR. Further-
more, double staining of the cells with anti-EGFR (FITC's
green signal) and anti-phosphorylated EGFR,i.e., activated
EGFR (TRITC's red signals) showed that in ACCS-AS and
NA-SCC cells the observed vacuole-like structure con-
tained only de-activated EGFR (the green mass lacking the
red signal, arrowheads, Fig 6). Results also suggested that
in ACCS cells, where EGFR expression is low, EGFR clus-
tering at focal adhesions was low (Fig 6). In these cells,
EGFR might either internalize into the cells (Fig. 6, ACCS
at 6 hours) and/or small undetectable vacuole-like struc-
tures might be formed and exocytosed. However, in
ACCS-AS, EGFR clusters were formed as early as 30 min-
utes, increased in size and formed marginal vacuoles then
were expelled. At 6 hours, gradual loss of attached viable
cells was observed with evidence of new EGFR clustering
at the rims of still viable attached cells (Fig 6).
Discussion
In this study, we have investigated the effects of a combi-
nation of tyrosine kinase inhibition of EGFR and uPAR
down-regulation on EGFR signaling pathway in adenoid
Cystic Carcinoma (ACC) cell lines. Then, the behaviors of
uPAR down-regulated cells were compared with NA-SCC
squamous carcinoma cells showing similar uPAR/EGFR
expression profile.
Molecular inhibition of EGFR/HER1 signaling is exten-
sively investigated as a promising cancer treatment strat-
egy[26]. The potential value of modulating EGFR
signaling as a cancer treatment approach is reflected by
the broad array of molecular inhibitors that have been
developed and launched in clinical trials during recent
years[27]. The majority of patients on clinical trials with
anti-EGFR agents have been enrolled within the past 3–5
years, and several dozen large-scale trials remain in
progress or in final design. Despite broad enthusiasm
regarding the potential value of EGFR target modulation
in cancer therapy, the field rests at an important cross-
roads in light of negative results from several large-scale
phase III clinical trials in lung cancer reported during
2002–2003 [28,29].
The side effects of EGFR tyrosine kinase inhibitors are
important challenges in their usage in cancer therapy. In
fact, inappropriate dosing could be the cause for the ele-
vated risk of toxicity[30,31] and one report, released in
2003, has claimed that 246 patients actually have died
from treatment itself [32].
For these reasons, recently, some authors have suggested
the value of Dual-Agent Molecular Targeting of the
EGFR[33]. They suggest that combined treatment with
distinct EGFR inhibitory agents can augment the potency
of EGFR signaling inhibition[33]. This approach suggests
potential new strategies to maximize effective target inhi-
bition, which may improve the therapeutic ratio for anti-
EGFR-targeted therapies in developing clinical trials.
On the other hand, recent studies suggested that uPAR
inhibition by RNA interference may be of great value for
curbing the growth and spread of cancers [34]. As men-
tioned previously, based on data from knock-out mice
studies, uPAR is not significantly important for the nor-
mal development and growth [7,8]. In fact, uPAR is rarely
expressed on the surface of normal cells and mostly is con-
sidered as a specific marker for cellular malignant
changes. For these reasons, it is targeted for cancer therapy
by some researchers[35,36].
We have established antisense induced down-regulation
of uPAR in ACCS cell lines (ACCS-AS)[24]. uPAR down-
regulation resulted in decreased adhesion, migration and
invasion on various ECMs [24]. In this paper we have
shown the results on collagen I (Fig. 2). A recent study on
osteosarcoma clones exhibiting uPAR down-regulation
also demonstrated decreased adhesion, migration and
invasion in cell-based assays in vitro[3]. In vivo study also
showed that injection of mice with more potent antisense
clones could completely prevent the pulmonary metasta-
sis in the mice model [3]. The results of other studies
working on glioblastoma also showed that cellular prolif-
eration of cells was not affected by uPAR down-regula-
tion[5,5].
uPAR antisense treatment led to an increase in EGFR
expression in ACCS-AS cells(Fig. 1, B). This was in agree-
ment with previous studies on HEp3 cell line[16]. The
increased EGFR in uPAR-down-regulated cells led us to
further investigate whether gefitinib as an EGFR inhibi-
tory agent has any effect on the behavior of our estab-
lished transfected cells. MTT assay showed the inhibitory
effects of gefitinib on cellular growth (Fig. 2). Interest-
ingly, although gefitinib inhibited the cellular prolifera-
tion, EGF did not increase it (Fig. 2). Lack of EGF-induced
cellular proliferation has been reported since two decades
ago [37]. In fact, EGF has been reported to both increase
and decrease proliferation [38]. It has been shown that
EGF inhibited cell proliferation and induced morpholog-
ical features in some cells. It is believed that in cells with
over-expressed EGFR, adding exogenous EGF induce
apoptosis by induction of dramatic increase in EGF-R
auto-phosphorylation, which down-regulate EGF signal
transduction[39].Molecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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De-activated EGFR constitutes the main component of the vacuole-like structure in ACCS-AS Figure 6
De-activated EGFR constitutes the main component of the vacuole-like structure in ACCS-AS: Cells were dou-
ble-stained with anti-EGFR (green) and anti-phosphorylated EGFR(red). Immunocytochemistry showed that vacuole-like struc-
ture formed in ACCS-AS cells upon gefitinib treatment contained mostly de-activated EGFR. Attached cells were markedly 
reduced at 6 hours. In ACCS cells, vacuole-like formations were not detected. At 6 hours, the number of attached cells was 
also reduced. In ACCS cells, there were some evidences of internalization of EGFR to the cytoplasm.Molecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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We showed that gefitinib de-phosphorylated EGFR and
ERK (Fig. 4). This was comparatively more intensive and
happened earlier in ACCS-AS cells, compared to parental
ACCS (Fig. 4). Delayed and less intensive in-activation of
ERK in ACCS could be attributed to uPAR-induced activa-
tion of ERK which is significantly suppressed in uPAR
down-regulated ACCS-AS [40].
Furthermore, as results of this study showed, EGFR accu-
mulated at focal adhesions upon de-activation by gefit-
inib (Fig 6). Localization of EGFR especially after bindings
of ligands is an interesting part of EGFR signaling. In
many cells, EGFR is found in caveolae [41]. Recently it has
been established that upon EGFR activation, EGFR clus-
ters dimerize and internalize [41-43]. Ligand-induced
internalization of EGFR is suggested to follow the migra-
tion of active receptors out of caveolae, and subsequent
receptor clustering over clathrin-coated vesicles [44,45].
These steps are suggested to enable the loading of monou-
biquitylated receptors onto an ubiquitin-bound multimo-
lecular complex that sorts ERBB1 in early endosomes.
EGFR is further processed to luminal vesicles of the pre-
lysosomal compartment [45,41]. In general, ligand-
induced receptor endocytosis down-regulates growth fac-
tor signaling. However, internalized EGFR molecules are
enzymatically active, hyperphosphorylated and associ-
ated with Shc, GRB2 and SOS[46] and endosomal EGFR
signaling is sufficient to activate the main signaling path-
ways leading to cell proliferation and survival [42].
Interestingly, in this study, we observed a specific pattern
of EGFR localization. In fact, videography showed a grad-
ual appearance of vacuole-like structures upon gefitinib
treatment in ACCS-AS (Fig. 5) as well as NA-SCC cells
(Data not shown). Time-laps videos also showed that
these vacuole-like structures were gradually undergoing
exocytosis in ACCS-AS and NA-SCC cells [Additional file
2, 3 and 4]. In ACCS, however, there was no significant
evidence of such vacuole formation. Interestingly, immu-
nocytochemical study showed that these vacuole-like
structures actually contained accumulated de-activated
EGFR (Fig. 6, red arrow heads). Furthermore, our results
suggested that upon gefitinib inhibition of EGFR activa-
tion in high EGFR/low uPAR cells, de-activated EGFR clus-
tered (Fig 6). These clusters apparently failed to
internalize. We speculate that the phenomenon might be
either due to accumulation of de-activated EGFR at focal
adhesion preventing their internalization or lowered
uPAR expression somehow affected mechanisms control-
ling EGFR trafficking. However, in ACCS cell line, with
high uPAR/low EGFR de-activated EGFR might cluster and
internalize in endosomes as shown by immunocytochem-
istry at 6 hours (Fig. 6).
Finally, considering the effect on adhesion and chemotac-
tic cell migration and proliferation, these results suggest
that targeting both EGFR and uPAR might provide an
alternative method on cancer control by inhibiting both
its growth and metastasis. Furthermore, increased sensi-
tivity of ACCS-AS cells to anti-tumor effects of lower doses
of tyrosine kinase inhibitors suggested that by inhibiting
both EGFR and uPAR, we might achieve further goals by
reducing unwanted side effects resulted from high doses
of such agents.
Materials and methods
Cells and culture
This study examined three human cell lines: ACCS [47-
49] and its stabilized uPAR antisense transfected clones;
i.e. ACCS-AS cells, as described previously [24] and NA-
SCC cells [49] isolated from tongue squamous cell carci-
noma. The cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 2 mM L-glutamine in a 5% CO2
incubator at 37°C. The antisense transfected cells were
maintained by Zeocin 100 ug/ml DMEM.
Total RNA preparation and real-time RT-PCR
Total RNA was extracted from cultured cells using Sigma
RNA-Easy kit, according to the manufacturer's protocol.
First-strand cDNA was synthesized from 3 μg of total RNA
using Superscript II reverse transcriptase (Life Technolo-
gies, Inc., Karlsruhe, Germany) and random hexanucle-
otide primers. The mRNA level of EGFR and uPAR was
quantified using real-time PCR. Real-time monitoring of
PCR products was performed by measuring the fluores-
cence (SYBR Green) of PCR products with the LightCycler
(Roche Molecular Biochemicals, Mannheim, Germany).
Normalization and quantification of RT-PCR were per-
formed using Light Cycler software (Roche Molecular Bio-
chemicals, Mannheim, Germany). The following sets of
primers were used: uPAR, forward primer 5-TTACCTAAT-
GCATTTCCT-3, reverse primer 5-TTGCACAGCCTCTTAC-
CATA-3; β-actin(as internal control), forward primer 5-
GTGGGGCGCCCCAGGCACCA-3, reverse primer 5-CTC-
CTTAATGTCACGCACGATTTC and EGFR, forward primer
5'GCGTCTCTTGCCGGAATGT3', reverse primer
5'CTTGGCTCACCCTCCAGAAG3'
Antibodies and reagents
Mouse anti-EGFR and anti-Phospho-EGFR were from BD
Biosciences (BD Biosciences, San Diego, CA). Rabbit anti-
EGFR was purchased from Chemicon (Chemicon, Temec-
ula, CA). TRITC-conjugated mouse IgG1 antibody and
FITC-conjugated anti rabbit IgG antibody were from
Sigma (Sigma, St Louis, MO). Anti-ERK and anti-Phospho
ERK antibodies were from Santa Cruz (Santa Cruz Bio-
technology Inc., Santa Cruz, CA, USA). Anti-Cyclin D1
rabbit polyclonal antibody(#2922) was from Cell Signal-Molecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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ing (Cell Signaling Technology, Beverly, MA, USA). Gefit-
inib (Iressa, ZD 1839) was obtained from AstraZeneca
(AstraZeneCa Inc, UK).
MTT Assay
The anti-proliferative activity of gefitinib was evaluated
using an MTT-based assay as described previously[50].
Briefly, cells were harvested, washed with calcium- and
magnesium-free PBS, re-suspended in DMEM and plated
at a density of 1 × 104 vital cells into triplicate wells of flat
bottom microtitration plates. Cells were allowed to
adhere for 12 hours. Then fresh DMEM containing either
DMSO or gefitinib at 0.5 uM; 3.75 uM; or 37.5 uM doses
were added to determine the proper gefitinib dose. For the
second step of MTT assay, serum-free DMEM containing
0.1%BSA, with either 100 ng/ml EGF, 3.75 μM gefitinib or
DMSO as control were added. Incubation was done for
24, 48, and 72 h, and the number of metabolically active
cells was determined. All experiments were repeated three
times in triplets.
Cell migration assay
A modified Boyden chamber was used for the cell chemo-
tactic migration assay, as described previously [51] with
brief modifications. The chamber (Falcon) consisted of
upper and lower compartments separated by a polyethyl-
ene terephthalate track-etched filter (6.4 mm diameter)
with 8 μm pores. The lower side of the filter was coated
with collagen I or bovine serum albumin (BSA). Sus-
pended cells (1 ~ 2 × 105 cells/well) in serum-free medium
containing 0.3% BSA were placed in the upper compart-
ment of the chamber and additional 100 ng/ml EGF, 3.75
μM gefitinib or DMSO (vehicle) were added. After 12
hours incubation at 37°C, migrated cells to the lower side
of the filter were quantified and cells in five randomly
chosen fields were counted. Counts were averaged and
corrected with BSA cell invasion as control.
Cell adhesion assay
Standard static adhesion assay was carried out as
described previously [51] using a 96-well microtiter plate
coated with collagen I or BSA. Briefly, 1~2 × 104 cells/well
in serum-free DMEM containing 0.3% BSA, simultane-
ously with or without 3.75 uM gefitinib were added to the
wells and allowed to adhere at 37°C for 60 min. Attached
cells were fixed with methanol, stained with 0.5% crystal
violet and lysed in 2% SDS. The absorbance was measured
at 590 nm with a microplate reader.
Evaluation of Morphology by Light Microscopy
Cells were harvested and plated in (Iwaki) non-coated
dishes overnight. The next day, serum-free DMEM was
aspirated and replaced with fresh serum-free DMEM with
3.75  μM gefitinib. Changes in cell morphology were
examined under a Nikon Eclipse TE300 light microscope
and photographed with a side attached Cool snap at
determined times.
Immunofluorescence staining
The cellular localization of focal adhesion components
was analyzed using indirect Immunofluorescence stain-
ing. Cells were plated over cover-slips and incubated in
serum-free DMEM for 12–16 hours then were treated with
gefitinib at 3.75 μM. Cells were fixed in 4% Paraformalde-
hyde in BPS. Cover-slips were incubated with first anti-
bodies for 1 h at room temperature, washed three
times(each time for 10 minutes) with PBS, and then incu-
bated with FITC-conjugated and/or TRITC-conjugated
secondary antibodies. The images were captured using a
CoolSNAP computer-controlled camera (Roper Scientific,
Trenton, NJ) CCD camera and subsequently processed for
analysis using Cool Snap software (Roper Scientific, Tren-
ton, NJ).
Immunoblotting analysis
Cells were harvested and plated in serum-free DMEM for
12–16 hrs then treated for 30, 60 min, and 6 hours with
3.75 μM gefitinib or non-stimulated(vehicle only). The
cells were lysed with Ripa lysis buffer and insoluble mate-
rial was pelleted at 14,000 rpm for 30 min at 4°C. Equal
amounts of proteins were diluted in same Ripa buffer and
sample buffer. The cell lysates were resolved by 10% SDS-
PAGE, transferred to a nitrocellulose membrane, and
incubated with specific primary antibodies. Protein bands
were visualized using HRP-conjugated secondary antibod-
ies and Enhanced Chemiluminescence Reagent (Amer-
sham Pharmacia Biotech, Buckinghamshire, United
Kingdom). Coomassie blue staining of the gels and
immunoblotting with β-actin were used for confirmation
of equal loading. The membranes were stripped using
Restore™ Plus western blot stripping buffer (Thermo Sci-
entific Inc., Rockford, IL, USA) blocked with skim milk
and re-probed for other antibodies.
Time-Lapse videography
Tissue culture plates were placed on the stage of a Nikon
Eclipse 300 TE inverted microscope equipped with phase-
contrast optics, a thermostatically controlled heating stage
(Lincam Scientific Instruments, Surrey, UK), and a Plex-
iglas incubator (Nikon, Yokohama, Japan). The tempera-
ture inside the incubator was maintained at 37°C using a
customized thermostatically controlled heating fan (DFA,
Copenhagen, Denmark). To perform the videography, a
CoolSNAP computer-controlled camera (Roper Scientific,
Trenton, NJ) was mounted on the microscope.
Statistical analysis
Comparisons between groups means were performed
with paired, two-tailed Student's t test. P values less than
0.05 were considered statistically significant. AdhesionMolecular Cancer 2008, 7:47 http://www.molecular-cancer.com/content/7/1/47
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data were collected from triplicate experiments as the
mean number of adherent cells in triplicate wells. The
means ± SD represent the compiled data from experi-
ments.
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